Logo image of NBTX

NANOBIOTIX SA - ADR (NBTX) Stock Fundamental Analysis

NASDAQ:NBTX - Nasdaq - US63009J1079 - ADR - Currency: USD

3.875  +0.12 (+3.06%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NBTX. NBTX was compared to 562 industry peers in the Biotechnology industry. NBTX may be in some trouble as it scores bad on both profitability and health. NBTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NBTX had negative earnings in the past year.
NBTX had a negative operating cash flow in the past year.
In the past 5 years NBTX always reported negative net income.
In the past 5 years NBTX always reported negative operating cash flow.
NBTX Yearly Net Income VS EBIT VS OCF VS FCFNBTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

NBTX's Return On Assets of -101.06% is on the low side compared to the rest of the industry. NBTX is outperformed by 76.87% of its industry peers.
Industry RankSector Rank
ROA -101.06%
ROE N/A
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBTX Yearly ROA, ROE, ROICNBTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NBTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBTX Yearly Profit, Operating, Gross MarginsNBTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

1

2. Health

2.1 Basic Checks

NBTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NBTX has more shares outstanding
NBTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NBTX has a worse debt to assets ratio.
NBTX Yearly Shares OutstandingNBTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NBTX Yearly Total Debt VS Total AssetsNBTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -10.65, we must say that NBTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.65, NBTX is doing worse than 76.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.65
ROIC/WACCN/A
WACC7.11%
NBTX Yearly LT Debt VS Equity VS FCFNBTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 1.04 indicates that NBTX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.04, NBTX is doing worse than 88.79% of the companies in the same industry.
A Quick Ratio of 1.04 indicates that NBTX should not have too much problems paying its short term obligations.
NBTX's Quick ratio of 1.04 is on the low side compared to the rest of the industry. NBTX is outperformed by 87.37% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 1.04
NBTX Yearly Current Assets VS Current LiabilitesNBTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

NBTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.33%.
The Revenue for NBTX has decreased by -138.62% in the past year. This is quite bad
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
Revenue 1Y (TTM)-138.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-154%

3.2 Future

NBTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.30% yearly.
The Revenue is expected to grow by 34.61% on average over the next years. This is a very strong growth
EPS Next Y33.28%
EPS Next 2Y27.18%
EPS Next 3Y25.69%
EPS Next 5Y26.3%
Revenue Next Year-3.32%
Revenue Next 2Y76.18%
Revenue Next 3Y47.95%
Revenue Next 5Y34.61%

3.3 Evolution

NBTX Yearly Revenue VS EstimatesNBTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 100M 200M 300M 400M 500M
NBTX Yearly EPS VS EstimatesNBTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NBTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBTX Price Earnings VS Forward Price EarningsNBTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBTX Per share dataNBTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

NBTX's earnings are expected to grow with 25.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.18%
EPS Next 3Y25.69%

More info and screens

0

5. Dividend

5.1 Amount

NBTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOBIOTIX SA - ADR

NASDAQ:NBTX (5/14/2025, 4:30:02 PM)

3.875

+0.12 (+3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-02 2025-04-02/amc
Earnings (Next)05-20 2025-05-20
Inst Owners24.66%
Inst Owner Change-1.02%
Ins Owners0.3%
Ins Owner ChangeN/A
Market Cap183.69M
Analysts86.67
Price Target12.94 (233.94%)
Short Float %0.01%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.3%
PT rev (3m)9.97%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)19.72%
EPS NY rev (3m)10.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)15.73%
Revenue NY rev (3m)24.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS-0.27
BVpS-1.54
TBVpS-1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.31%
Cap/Sales -7.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 1.04
Altman-Z -10.65
F-Score2
WACC7.11%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)20.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
EPS Next Y33.28%
EPS Next 2Y27.18%
EPS Next 3Y25.69%
EPS Next 5Y26.3%
Revenue 1Y (TTM)-138.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-154%
Revenue Next Year-3.32%
Revenue Next 2Y76.18%
Revenue Next 3Y47.95%
Revenue Next 5Y34.61%
EBIT growth 1Y-155.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.61%
EBIT Next 3Y27.91%
EBIT Next 5Y36.1%
FCF growth 1Y-59.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.71%
OCF growth 3YN/A
OCF growth 5YN/A